-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On December 9, 2021, the Phase I clinical trial of YS-ON-001, an innovative drug independently developed by EsenBio, was held in Tianjin Cancer Hospital
It is reported that YS-ON-001 is a biological preparation developed based on PIKA adjuvant
Through studying its mechanism of action, the researchers found that the drug can significantly enhance the activation level of macrophages and dendritic cells, increase the expression of cytokines, enhance the activation level of NK cells and NKT cells in the tumor microenvironment, and down-regulate the regulation.
Pharmacodynamic research results show that YS-ON-001 has a high tumor growth inhibition rate in animal models of breast cancer, lung cancer, liver cancer, colorectal cancer and prostate cancer